milrinone has been researched along with Tachycardia, Ventricular in 8 studies
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 7.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 7.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 6.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 5.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| "Milrinone infusion is one of a few select "non-device" therapies for patients with New York Heart Association (NYHA) class IV, stage D heart failure, which has been associated with an increase in ventricular tachyarrhythmia and atrial fibrillation." | 3.96 | Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias. ( Achu, E; Alpert, JS; Baran, DA; Cassuto, J; Goldschmidt, M; Harhash, AA; Hussein, A; Zucker, MJ, 2020) |
| "To evaluate the pharmocokinetics of intravenous milrinone in patients with severe congestive heart failure during continuous venovenous hemofiltration (CVVH)." | 3.70 | Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration. ( Matsumoto, H; Okeie, K; Saito, S; Shibata, K; Taniguchi, T, 2000) |
| " Patients were maintained on milrinone therapy for as long as 8 weeks and demonstrated a low incidence of adverse cardiac (7%) or noncardiac (4%) events." | 2.68 | Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. ( Kapoor, C; Mehra, MR; Smart, FW; Stapleton, DD; Ventura, HO; Zimmerman, D, 1997) |
| "Bacteremia was the most common type of infection." | 1.43 | Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy. ( Acharya, D; Hashim, T; Loyaga-Rendon, RY; Morgan, CJ; Pamboukian, SV; Revilla-Martinez, M; Sanam, K; Tallaj, JA, 2016) |
| "Hypothermia has been reported to induce ventricular tachycardia and fibrillation (VT/VF) in patients with early repolarization (ER) pattern." | 1.40 | Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone. ( Antzelevitch, C; Gurabi, Z; Koncz, I; Nesterenko, VV; Patocskai, B, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer-Perl, M | 1 |
| Sadon, S | 1 |
| Zahler, D | 1 |
| Milwidsky, A | 1 |
| Sadeh, B | 1 |
| Sapir, O | 1 |
| Granot, Y | 1 |
| Korotetski, L | 1 |
| Ketchker, L | 1 |
| Rosh, M | 1 |
| Banai, S | 1 |
| Havakuk, O | 1 |
| Harhash, AA | 1 |
| Cassuto, J | 1 |
| Hussein, A | 1 |
| Achu, E | 1 |
| Zucker, MJ | 1 |
| Goldschmidt, M | 1 |
| Alpert, JS | 1 |
| Baran, DA | 1 |
| Cox, ZL | 1 |
| Calcutt, MW | 1 |
| Morrison, TB | 1 |
| Akers, WS | 1 |
| Davis, MB | 1 |
| Lenihan, DJ | 1 |
| Gurabi, Z | 2 |
| Koncz, I | 2 |
| Patocskai, B | 2 |
| Nesterenko, VV | 1 |
| Antzelevitch, C | 2 |
| Acharya, D | 1 |
| Sanam, K | 1 |
| Revilla-Martinez, M | 1 |
| Hashim, T | 1 |
| Morgan, CJ | 1 |
| Pamboukian, SV | 1 |
| Loyaga-Rendon, RY | 1 |
| Tallaj, JA | 1 |
| Barajas-Martinez, H | 1 |
| Hu, D | 1 |
| Mehra, MR | 1 |
| Ventura, HO | 1 |
| Kapoor, C | 1 |
| Stapleton, DD | 1 |
| Zimmerman, D | 1 |
| Smart, FW | 1 |
| Taniguchi, T | 1 |
| Shibata, K | 1 |
| Saito, S | 1 |
| Matsumoto, H | 1 |
| Okeie, K | 1 |
1 trial available for milrinone and Tachycardia, Ventricular
| Article | Year |
|---|---|
Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Topics: Adult; Aged; Cardiotonic Agents; Cohort Studies; Dobutamine; Drug Administration Schedule; Drug Ther | 1997 |
7 other studies available for milrinone and Tachycardia, Ventricular
| Article | Year |
|---|---|
Repetitive milrinone therapy in ambulatory advanced heart failure patients.
Topics: Adrenergic beta-Antagonists; Aged; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Huma | 2022 |
Safety of Outpatient Milrinone Infusion in End-Stage Heart Failure: ICD-Level Data on Atrial Fibrillation and Ventricular Tachyarrhythmias.
Topics: Aged; Atrial Fibrillation; Cardiotonic Agents; Defibrillators, Implantable; Dose-Response Relationsh | 2020 |
Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction.
Topics: Adult; Aged; Cardiac Catheterization; Cardiotonic Agents; Creatinine; Defibrillators, Implantable; F | 2013 |
Cellular mechanism underlying hypothermia-induced ventricular tachycardia/ventricular fibrillation in the setting of early repolarization and the protective effect of quinidine, cilostazol, and milrinone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cilostazol; Disease Models, Animal; Dogs; Electr | 2014 |
Infections, Arrhythmias, and Hospitalizations on Home Intravenous Inotropic Therapy.
Topics: Administration, Intravenous; Adult; Aged; Alabama; Atrial Fibrillation; Bacteremia; Cardiotonic Agen | 2016 |
Cellular and ionic mechanisms underlying the effects of cilostazol, milrinone, and isoproterenol to suppress arrhythmogenesis in an experimental model of early repolarization syndrome.
Topics: Action Potentials; Animals; Cardiac Electrophysiology; Cardiovascular Agents; Cilostazol; Death, Sud | 2016 |
Pharmacokinetics of milrinone in patients with congestive heart failure during continuous venovenous hemofiltration.
Topics: Adult; Aged; Biological Availability; Female; Heart Failure; Hemodynamics; Hemofiltration; Humans; I | 2000 |